Skip to main content
. 2009 Oct 7;101(19):1308–1324. doi: 10.1093/jnci/djp280

Figure 2.

Figure 2

Progression-free interval and KRAS mutation status of tumor in patients with metastatic colorectal cancer who were randomly assigned to treatment with best supportive care (BSC) alone or panitumumab (Panit) plus BSC in a phase III study (27). A) Tumors with mutant KRAS status. B) Tumors with wild-type KRAS status (27) (with permission from the American Society of Clinical Oncology). CI = confidence interval; HR = hazard ratio.